with only limited palliative treatment available, many patients die in childhood or early adulthood. A major focus of current research is to determine the paradox of how primary genetic defects in ubiquitously expressed nuclear proteins translate to tissue-specific effects.
We have rationalized that the cellular context in which the mutated LMNA is expressed is the primary cause for the observed clinical phenotype(s) associated with LMNA mutations. Thus, LMNA must interact with factors that are unique to this specific tissue. To test this hypothesis, we screened a human ventricular heart cDNA library with LMNA in a yeast 2-hybrid interaction assay. From this screen, we discovered MLIP (aka C6orf142 in human and 2310046A06rik in mouse), a unique single-copy gene that is an innovation of amniotes (reptiles, birds, and mammals). As described in our original article, MLIP is expressed ubiquitously and most abundantly in human and mouse heart, and skeletal and smooth muscle. 2 We identified that the MLIP gene expresses at least 7 alternatively spliced protein variants in the mouse heart that range in size from 23 to 57 kDa, and they possess several novel structural motifs not found in any other protein. 2 Huang et al 1 have now added Isl1, an essential transcription factor for cardiac progenitor cell specification, 7 as a new MLIP protein interactor. This raises many new and intriguing questions as to the biological role of MLIP in the heart, particularly in light of A-type lamins that are primarily expressed only after the commitment of cells/tissues. 8 Both A-type lamins and Isl1 play critical roles in the regulation of gene expression.
We recently presented at 2011 American Heart Association Scientific Session that MLIP haploinsufficiency results in hypertrophic hearts that are functionally dilated. 3 Huang et al 1 provide data that indicate MLIP expression is reduced in an in vitro agonist-induced cardiomyocyte hypertrophy model and that overexpression of MLIP in this model blocks agonist-mediated cardiomyocyte hypertrophy. Huang et al presented protein expression data that show only one of the MLIP isoforms from their hypertrophy model, despite the fact that both of our groups have reported that the MLIP gene encodes for at least 7 alternatively spliced forms of MLIP. 1, 2 Which MLIP isoform is shown and do the levels of other MLIP splice forms change with hypertrophy?
Our original MLIP data were published 6 months before submission by Huang et al 1 to Circulation Research. Although they acknowledge this by citing our Journal of Biological Chemistry article, they still felt it necessary to rename the MLIP gene as cardiac Isl1-interacting protein (which is an alias often used for cyclin-dependent kinase inhibitor 1A), despite presenting identical nucleotide and amino acid sequence that we had already published in our original MLIP article. Furthermore, MLIP was acknowledged as the official name and symbol for this gene by both Human Genome Organization and National Center for Biotechnology Information shortly after our article was in press (April 15, 2011). The Human Genome Organization Gene Nomenclature Committee, which is a nonprofit organization, has done tremendous work in the standardization of naming more than ≈13 000 human genes so as to avoid confusion and contribute to proper database organization to advance research. The study by Huang et al 1 is largely confirmatory of the work by Ahmady et al, 2 and it is obvious that the gene coined cardiac Isl1-interacting protein by Huang et al 1 is actually MLIP. It is only appropriate that this error be corrected in line with internationally accepted standards for gene nomenclature to avoid any future confusion over the identity of MLIP. This is particularly important because MLIP is a newly discovered gene that interacts with both A-type lamin and Isl1 and may potentially serve as a transcriptional regulator that impacts genes involved in cardiac development, growth, and function, thus providing a new signaling paradigm to explore.
